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Hypertrophic Cardiomyopathy?We thank Dr. Baudhuin and colleagues for their letter
regarding our recent article (1). They raise the very
important and topical issue of DNA variant classiﬁ-
cation in determining whether a genetic ﬁnding is
pathogenic, benign, or a variant of uncertain signiﬁ-
cance (VUS). As Dr. Baudhuin and colleagues would
be aware, major international initiatives are being
established to develop robust and reliable classiﬁca-
tion criteria to determine the pathogenicity of DNA
variants in hypertrophic cardiomyopathy (HCM), and
indeed all other cardiovascular genetic diseases. Such
classiﬁcation systems and variant interpretation need
to take into account rapidly evolving human genetic
databases such as the Exome Aggregation Consortium
(ExAC), 1000 Genomes Project, Exome Variant Server
(ESV), and most recently, the Genomics England
100,000 Genomes Project, as well as in silico tools
(such as polyphen2 and SIFT), functional data, and
cosegregation studies in families.
Signiﬁcantly, the ﬁnal outcome of the genetic
evaluation is “probabilistic,” that is, it is not a “yes/
no” answer but rather a probability that the variant
identiﬁed causes disease on the basis of the available
supporting evidence (2,3). Dr. Baudhuin and col-
leagues correctly point out that over time, variant
classiﬁcations can change due to new information,
and this can change the classiﬁcation from patho-
genic to VUS or benign, and alternatively from VUS to
pathogenic. We agree that this is a product of the
rapid escalation of available genetic information due
to newer, faster, and cheaper sequencing technolo-
gies, and highlights the importance of periodic
re-evaluation of all variants. In HCM, we have previ-
ously reported that reclassiﬁcation is required in up
to 10% of families with HCM (4). Furthermore,
the issues surrounding variant classiﬁcation highlight
the urgent need to have organized collaborative in-
ternational efforts to curate all human disease genesand to develop classiﬁcation systems directly rele-
vant to cardiovascular disease. The recently pub-
lished American College of Medical Genetics and
Genomics guidelines are an important ﬁrst step in this
process, but need signiﬁcant adaptation and modiﬁ-
cation for such guidelines to be reliable and accurate
in the speciﬁc interpretation of variants relevant to
cardiovascular disease. To this end, the recently
developed National Institutes of Health–funded
Clinical Genome Resource (ClinGen) initiative pro-
vides the hope of improving genomic interpretation
by a coordinated international effort from both clin-
ical and research communities, with the key goals to
share data, build knowledge, develop and reﬁne
variant classiﬁcation, and improve care.
Importantly, the revised estimated prevalence
of HCM of up to 1 in 200 people is on the basis of several
factors in addition to the rate of pathogenic mutations
in what are known as highly intolerant sarcomere
genes. Advanced imaging techniques with high-
resolution cardiovascular magnetic resonance provide
more reliable diagnosis by identifying left ventricular
hypertrophy not appreciated with echocardiography,
expanded recognition of the genotype-positive,
phenotype-negative subset, while more comprehen-
sive family-based clinical and genetic surveillance and
higher clinical index of suspicion is resulting in more
asymptomatic patients being identiﬁed with HCM
(Central Illustration in Semsarian et al. [1]). Taking
together all of these considerations, HCM appears
more prevalent than current estimates, promoting
greater visibility for the disease, enhancing diagnosis
and consideration of contemporary treatment options
(5), and ultimately improving care and outcomes in
patients and families with HCM worldwide.Christopher Semsarian, MBBS, PhD, MPH
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Endocarditis in the
United StatesThe paper by Pant et al. (1) and the editorial by Dayer
and Thornhill (2) provided further insight into
the recent pattern of endocarditis hospitalizations in
the United States, and the potential causes behind the
changes. However, we have several concerns about
the paper and the associated editorial. Whereas Pant
et al. (1) declared, “There is scant data on IE trends
since this major practice change in the United States,”
we had published an article in the Journal on the
same topic in 2013 (3), which was unfortunately
missed by Pant et al.
Further, Pant et al. (1) provided subgroup results
stratiﬁed by the potential causative organisms. How-
ever, although potentially interesting, the limitations
of this analysis need highlighting. As appropriately
indicated by Dayer and Thornhill (2), the codes used
by Pant et al. (1) are likely inadequate for diagnosing
organisms. Although using discharge diagnosis codes
for endocarditis has been previously validated against
the Duke criteria (4,5), we are unaware of validation
studies for organism codes used by Pant et al. (1).
Whereas they show an increase in staphylococcal and
streptococcal endocarditis, it is unclear whether it is
due to better diagnostics, change in the coding pat-
terns, double counting the same patients, a real surge
in disease occurrence, or a mix of these. The fact that
there has been an increase in gram-negative, staphy-
lococcal, streptococcal, and fungal endocarditis raises
our suspicion for better diagnostics, or change in
coding patterns; at least as partial contributors.
We should also clarify that the study by Pant et al.
(1), similar to ours, was not a study of true incidence,
but one that determined the hospitalization rates.
Our study is also misrepresented in the editorial by
Dayer and Thornhill (2). They state: “Bikdeli et al.
looked at admissions of patients older than 65 years
by using Medicare inpatient Standard Analytic
Files. They recorded a reduction in the absolute
numbers, but no correction was made for the absolute
numbers of patients enrolled in Medicare eligible fortreatment.” We are surprised by this comment,
because as could be inferred from our paper, even the
title, we had determined the trends in hospitalization
rates, not merely number of hospitalizations.Behnood Bikdeli, MD
Yun Wang, PhD
*Harlan M. Krumholz, MD, SM
*Center for Outcomes Research and Evaluation (CORE)
Yale University School of Medicine
1 Church Street, Suite 200
New Haven, Connecticut 06510
E-mail: harlan.krumholz@yale.edu
http://dx.doi.org/10.1016/j.jacc.2015.06.1353
Please note: Dr. Krumholz has received grants, through Yale University, from
Medtronic, Johnson & Johnson (Janssen), and United Health. Drs. Wang and
Bikdeli have reported that they have no relationships relevant to the contents
of this paper to disclose.
REF ER ENCES
1. Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis inci-
dence, microbiology, and valve replacement in the United States from 2000
to 2011. J Am Coll Cardiol 2015;65:2070–6.
2. Dayer M, Thornhill M. Antibiotic prophylaxis guidelines and infective
endocarditis: cause for concern? J Am Coll Cardiol 2015;65:2077–8.
3. Bikdeli B, Wang Y, Kim N, Desai MM, Quagliarello V, Krumholz HM. Trends
in hospitalization rates and outcomes of endocarditis among Medicare bene-
ﬁciaries. J Am Coll Cardiol 2013;62:2217–26.
4. Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P. Increasing
incidence and mortality of infective endocarditis: a population-based study
through a record-linkage system. BMC Infect Dis 2011;11:48.
5. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Vet-
eran’s affairs hospital discharge databases coded serious bacterial infections
accurately. J Clin Epidemiol 2007;60:397–409.REPLY: Hospitalizations for Endocarditis
in the United StatesWe would like to thank Dr. Bikdeli and colleagues for
their interest in our paper (1). We do apologize for not
citing the work by Bikdeli et al. (2) on the trends in
hospitalization rates and outcomes of endocarditis
among Medicare beneﬁciaries (1). The difference in
results seen in our paper from the Bikdeli et al. (2)
paper could be because of differences in study pop-
ulation and follow-up duration. We acknowledge the
potential limitation related to coding that could in-
ﬂuence the results of our study as well as other
retrospective studies done on this topic, as pointed
out by Bikdeli et al. (2). Hence, the conclusions made
from the observational studies should be considered
as “hypothesis generating” and not a “causal rela-
tionship.” Prospective studies providing insight into
the impact of the guideline is indeed lacking, and
we have echoed the dire need for such study, which
has been emphasized in the accompanying editorial
by Dayer and Thornhill (3). Nonetheless, a common
